| Patient | Nelson Mandela |
|---|---|
| Date of birth | 1918-07-18 |
| Identifiers | MRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718 |
| Document date | 2001-07-14 |
| Author | Thandiwe Mokoena, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month follow-up on androgen deprivation, ten days before radiotherapy. [S]
Mr. Mandela returns three months after his last visit, twelve weeks after his first leuprolide injection. He completed four weeks of bicalutamide. Hot flashes continue three or four times a week and are mild; his energy is a little lower in the afternoons, and he still walks every morning. His weight is up 1.2 kg since starting treatment. He has had no breast tenderness, chest pain, breathlessness, or leg swelling, and his mood and memory are unchanged. Fiducial markers were placed and the planning scans done a week ago, without complications. Radiotherapy starts in ten days. Urinary symptoms are unchanged. The audiology test after his wellness visit showed mild high-frequency hearing loss on the left, and he is thinking about a hearing aid. He takes vitamin D every day. [S]
| Element | Detail |
|---|---|
| Androgen deprivation | Twelve weeks on leuprolide; second injection given today |
| Side effects | Mild hot flashes; slightly lower afternoon energy; weight up 1.2 kg |
| Radiotherapy | Fiducial markers placed and planning done; treatment starts in ten days |
| Hearing | Mild high-frequency loss on the left on audiology |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly lower afternoon energy; weight up 1.2 kg |
| Endocrine | Positive | Mild hot flashes three or four times a week; no breast tenderness |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Genitourinary | Positive | Mild urinary frequency, unchanged; no blood in the urine |
| Psychiatric | Negative | Mood good; PHQ-2 score 1; no change in memory |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide | One tablet once daily for four weeks | Oral route | 2001-04-14 to 2001-05-12 | completed | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapy | One injection every twelve weeks, two doses | Intramuscular route | 2001-04-21 to 2001-10-06 | completed | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2001-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2001-07-14 | Body height | 183 | cm | S |
| 2001-07-14 | Body weight | 81.6 | kg | S |
| 2001-07-14 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2001-07-14 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2001-07-14 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2001-07-14 | Heart rate | 70 | /min | S |
| 2001-07-14 | Respiratory rate | 14 | /min | S |
| 2001-07-14 | Body temperature | 36.6 | Cel | S |
| 2001-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2001-07-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.9 | ng/mL | <=4 ng/mL | Normal | S |
| 2001-07-14 | Testosterone [Mass/volume] in Serum or Plasma | 18 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 2001-07-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2001-07-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 2001-07-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 134/78 mm Hg; no ankle swelling |
| Chest | No gynecomastia |
| Perineum | Fiducial insertion sites healed |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed | C61 | S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D). |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition | active | confirmed | Z79.899 | S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed | Z86.11 | S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA on androgen deprivation | Every 3 to 6 months | Completed today | 0.9 ng/mL, down from 6.4 |
| Laboratory | Testosterone | Every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Completed today | 18 ng/dL, castrate |
| Laboratory | 25-hydroxyvitamin D | Three months after starting a supplement | Completed today | 34 ng/mL, up from 26 |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipid panel | Baseline and yearly on androgen deprivation | Up to date | Baseline four months ago; next in eight months |
| Imaging | Bone density (DXA) | Every 1 to 2 years on androgen deprivation | Up to date | Baseline three months ago |
| Examination | Blood pressure, weight, and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 134/78 mm Hg; weight 81.6 kg, up 1.2 kg since starting; no cardiac symptoms |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Completed today | Mild hot flashes three or four times a week; mild afternoon fatigue; no treatment wanted |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Survey | Cognition | Periodically on androgen deprivation | Up to date | Mini-Cog 5 of 5 at the wellness visit five weeks ago; no change reported |
| Survey | Urinary symptoms | Before radiotherapy, then every follow-up visit | Completed today | Mild frequency, unchanged from the baseline IPSS of 7 |
| Survey | Bowel function before radiotherapy | Baseline before radiotherapy, then every visit after it | Deferred | Not asked today, a deviation from the protocol; the visit was taken up by the androgen deprivation results and the radiotherapy plan. To be checked at the next visit |
| Medication safety | Second leuprolide injection | Every twelve weeks for two doses | Completed today | Given today in this clinic |
| Self-management | Physical activity and calcium intake | Every visit | Completed today | Walking every morning; resistance exercise twice a week; calcium from food |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022); Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026)
Follow-up: Radiotherapy from ten days' time, with weekly radiation oncology review. Primary care follow-up six weeks after radiotherapy ends, with PSA and testosterone. Next scheduled visit 2001-10-27: follow-up six weeks after radiotherapy: PSA, urinary and bowel effects, end of androgen deprivation, and the surveillance plan. [S]